Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

被引：39

作者：

Abdul-Ghani, Muhammad ^{[1
,2
]}

Puckett, Curtiss ^{[1
,2
]}

Adams, John ^{[1
,2
]}

Khattab, Ahmad ^{[1
,2
]}

Baskoy, Gozde ^{[1
,2
]}

Cersosimo, Eugenio ^{[1
,2
]}

Triplitt, Curtis ^{[1
,2
]}

DeFronzo, Ralph A. ^{[1
,2
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA

[2] Texas Diabet Inst, San Antonio, TX USA

来源：

DIABETES CARE | 2021年 / 44卷 / 02期

基金：

美国国家卫生研究院;

关键词：

BETA-CELL FUNCTION; EXENATIDE PLUS PIOGLITAZONE; GLUCOSE-TOLERANCE; INSULIN SENSITIVITY; BASAL/BOLUS INSULIN; TYPE-2; METFORMIN; TRIUMVIRATE; PREVENTION; PARADIGM;

D O I：

10.2337/dc20-0978

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVE To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 diabetes mellitus (T2DM) versus sequential addition of metformin followed by glipizide and insulin. RESEARCH DESIGN AND METHODS Drug-naive patients (N = 318) with new-onset T2DM were randomly assigned to receive for 3 years either 1) combination therapy with metformin, pioglitazone, and exenatide (triple therapy) or 2) sequential addition of metformin followed by glipizide and insulin (conventional therapy) to maintain HbA(1c) at <6.5% (48 mmol/mol). Insulin sensitivity and beta-cell function were measured at baseline and 3 years. The primary outcome was the difference in HbA(1c) between the groups at 3 years. RESULTS Baseline HbA(1c) +/- SEM values were 9.0% +/- 0.2% and 8.9% +/- 0.2% in the triple therapy and conventional therapy groups, respectively. The decrease in HbA(1c) resulting from triple therapy was greater at 6 months than that produced by conventional therapy (0.30% [95% CI 0.21-0.39]; P = 0.001), and the HbA(1c) reduction was maintained at 3 years in patients receiving triple therapy compared with conventional therapy (6.4% +/- 0.1% and 6.9% +/- 0.1%, respectively), despite intensification of antihyperglycemic therapy in the latter. Thus, the difference in HbA(1c) between the two treatment groups at 3 years was 0.50% (95% CI 0.39-0.61; P < 0.0001). Triple therapy produced a threefold increase in insulin sensitivity and 30-fold increase in beta-cell function. In conventional therapy, insulin sensitivity did not change and beta-cell function increased by only 34% (both P < 0.0001 vs. triple therapy). CONCLUSIONS Triple therapy with agents that improve insulin sensitivity and beta-cell function in patients with new-onset T2DM produces greater, more durable HbA(1c) reduction than agents that lower glucose levels without correcting the underlying metabolic defects.

引用

页码：433 / 439

页数：7

共 24 条

[1] Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial [J].